



FARA/RepliGen Webinar – Tuesday July, 26th 1:00pm EST

FARA has facilitated an opportunity for the FA community to get an update from RepliGen on their HDAC inhibitor program for FA. Drs. James Rusche, srVP, Research and Development, and Walter Herlihy, President and CEO, will provide a detailed update on the company's pre-clinical efforts to advance HDAC inhibitors for FA. In addition, we hope to facilitate a discussion regarding some of the hurdles and challenges that have been encountered and how the FA community can support RepliGen in their efforts. There will be time for Q&A.

Participation is limited to 20 individuals; however the webinar will be recorded so that it can be shared later with the entire community. Registration for participation is on a first come - first serve basis via this event registration website

<http://www.eventzilla.net/web/event?eventid=201107122743>

Registration is free of charge. In order to participate you will need access to a computer with internet connection during the time of the webinar and either a headset (speakers and microphone) or a telephone to fully participate.

Due to limited space available we ask that only one person in a family register. Of note, one person can register but several may actually listen and observe the meeting from a single computer.

More detailed instructions about connecting to the webinar and participation will be provided once registration is complete.